ZENTALIS PHARMACEUTICALS INC (ZNTL)
US98943L1070 - Common Stock
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Becomes Oversold (ZNTL)
Commit To Buy Zentalis Pharmaceuticals At $5, Earn 6.5% Annualized Using Options
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis files automatic mixed securities shelf (NASDAQ:ZNTL)
Zentalis (ZNTL) filed a prospectus related to a mixed shelf offering. This prospectus is not an offer to sell these securities. More on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals GAAP EPS of -$4.47 beats by $0.06 (NASDAQ:ZNTL)
Zentalis Pharmaceuticals reports full-year 2023 financial results and operational updates, beating earnings expectations with a cash balance of $483...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data...
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced...
Notable Thursday Option Activity: CVX, ZNTL, TWLO
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Oversold Conditions For Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals director purchases 17K company shares (NASDAQ:ZNTL)
Zentalis Pharmaceuticals director David Michael Johnson purchased 17,000 shares for $167,943, amidst a series of insider trades on the company in the past...
Wedbush cuts Zentalis to neutral, cites strategy shift for ovarian cancer drug (ZNTL)
Wedbush downgrades Zentalis (ZNTL) to neutral, citing uncertainties around the company's strategy shift for its drug azenosertib in ovarian cancer. Read more here.
Noteworthy Tuesday Option Activity: BTU, ZNTL, AKAM
Zentalis stock falls as Leerink cuts on data for lead asset
Zentalis Pharma (ZNTL) shares fell Tuesday after Phase 1 data for its lead cancer drug azenosertib, led to a downgrade at Leering Partners. Read more here.
Oversold Conditions For Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Commit To Buy Zentalis Pharmaceuticals At $15, Earn 17.9% Annualized Using Options
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Oversold Conditions For Zentalis Pharmaceuticals (ZNTL)
Investors Pick Up ZNTL Even Cheaper Than Its Secondary Stock Offering
Zentalis Pharmaceuticals (ZNTL) Shares Cross Below 200 DMA
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing ...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...